Latest news with #PrismRA®
Business Wire
5 days ago
- Health
- Business Wire
Scipher Medicine Unveils New Tool to Predict Rheumatoid Arthritis Treatment Success at EULAR 2025
WALTHAM, Mass.--(BUSINESS WIRE)--At the European Congress of Rheumatology (EULAR) 2025, Scipher Medicine, the company behind the groundbreaking PrismRA ® test, unveiled a new, AI-driven approach to help doctors better evaluate if a rheumatoid arthritis (RA) treatment is truly working — a challenge that has long frustrated both patients and physicians. This new 'RA Response Calculator,' developed using real-world patient data and machine learning, offers a more accurate way to determine whether someone is actually improving on their current therapy — cutting through the noise of subjective measures like patient self-reports and physician assessments. 'Anyone living with RA knows that figuring out whether a medication is working can take months — and even then, it's often unclear,' said Reg Seeto, CEO of Scipher Medicine. 'We created this tool to make that process faster, clearer, and more personalized. It brings science and objectivity to a space that's long relied on educated guesswork.' The study analyzed data from nearly 1,500 RA patients receiving commonly prescribed treatments — TNF inhibitors, T-cell inhibitors, and IL-6 inhibitors. By applying a machine learning algorithm to joint tenderness, swelling, and inflammation data collected over 24 weeks, Scipher's team identified a combination of two standard clinical measures that best predicts therapy success: Tender Joint Count (TJC) and Swollen Joint Count (SJC). The result: a simple formula that predicts whether a treatment is helping — or if it's time to try something else. 'Doctors already use TJC and SJC in the clinic. What's new is how we've mathematically combined them using real-world data and AI to create a consistent, data-backed benchmark for treatment response,' said Seeto. 'This is about giving providers and patients a clearer, faster answer — and a better shot at remission.' The new tool also showed improved accuracy over standard response metrics like CDAI and ACR scores, which are commonly used in trials but often fall short in real-world care. About Scipher Medicine Scipher Medicine is transforming how autoimmune diseases like RA are treated by using AI and network biology to match patients with therapies that actually work. Through its SPECTRA Rx and Dx platforms, Scipher combines the largest clinico-genomic dataset in rheumatology with real-world medical records, creating powerful tools to personalize care and improve drug development. Learn more at PrismRA is a first-of-its-kind blood test that helps doctors identify which RA patients are unlikely to respond to TNF inhibitor therapy — the most commonly prescribed (and most expensive) class of RA drugs. With just a routine blood draw, PrismRA analyzes a patient's molecular signature to guide more effective and personalized treatment plans. Visit to learn more.
Business Wire
16-06-2025
- Business
- Business Wire
Scipher Medicine expands its global presence, bringing precision medicine to Latin America through an alliance with Grupo Amarey
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leading precision immunology company, today announced a strategic alliance with Grupo Amarey, a leading company in the representation and distribution of technologies, solutions, and services for the healthcare sector in Colombia, Panama, and Costa Rica, to expand the global reach of its innovative precision diagnostic, PrismRA ®. This collaboration marks Scipher Medicine's first international expansion, bringing personalized medicine solutions to patients with rheumatoid arthritis (RA) in Latin America, starting with Colombia. PrismRA is the first molecular test of its kind that provides objective data to help healthcare professionals select the most effective biologic therapy for each RA patient, improving clinical outcomes and reducing unnecessary and ineffective treatments. 'Our mission at Scipher Medicine is to eliminate the trial-and-error approach in the treatment of autoimmune diseases by providing physicians with actionable, data-driven insights,' said Reg Seeto, CEO of Scipher Medicine. 'Expanding into Latin America, starting with Colombia through our partnership with Grupo Amarey, is a key step in our global strategy. Grupo Amarey's deep understanding of the local healthcare system and its commitment to innovation make them the ideal partner to bring PrismRA to the patients who can benefit most.' With its extensive experience and strong presence in the healthcare market in Colombia, Grupo Amarey is in a privileged position to facilitate the adoption and integration of PrismRA into clinical practice. 'We are excited to partner with Scipher Medicine to introduce PrismRA in Colombia,' said Dr. Manuel Camacho, General Manager of Grupo Amarey. 'Precision medicine holds tremendous potential to improve patient care, especially in complex diseases like rheumatoid arthritis. This collaboration reinforces our commitment to bringing cutting-edge diagnostic tools and new therapies to patients and healthcare professionals in Colombia, promoting more personalized and effective treatment decisions.' The terms of the agreement were not disclosed. This alliance highlights Scipher Medicine's commitment to advancing precision medicine globally, as well as Grupo Amarey's leadership in strengthening healthcare services in Latin America. About Scipher Medicine: Scipher Medicine drives the probability of success at each stage of drug development, from discovery to commercialization, by combining artificial intelligence with network biology and proprietary data, through its SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico-genomic data asset and biobank, along with electronic medical records (EMR) data for more than 3 million rheumatology patients. For more information, visit: About PrismRA: PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients worldwide. From a routine blood draw, the PrismRA test analyzes the patient's individual molecular signature, helping to identify those who are unlikely to adequately respond to TNFi therapy, the world's best-selling drug class, so that alternative effective therapies can be prescribed, avoiding unnecessary dose escalations or drug cycles. Physicians now have objective data to inform therapeutic decision-making and give patients the best chance to achieve treatment targets and improve clinical outcomes. For more information, visit: About Grupo Amarey Grupo Amarey is a leading company in the representation and distribution of technologies, solutions, and services for the healthcare sector in Colombia, Panama, and Costa Rica. Through partnerships with high-quality international brands, Grupo Amarey brings innovation in areas such as diagnostics, medical devices, biotechnology, laboratory, specialized surgical technologies, and hospital supplies, contributing to improved healthcare delivery and patient quality of life in the region. For more information, visit:
Business Wire
11-06-2025
- Business
- Business Wire
Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design
BUSINESS WIRE)--Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA®, Scipher's proprietary precision medicine diagnostic, into an ongoing trial. PrismRA is designed to analyze a patient's molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies. This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit. "We are incredibly pleased to partner with one of the world's leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process," said Reg Seeto, CEO of Scipher Medicine. "This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently." Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry. The specific terms of the collaboration were not disclosed. About Scipher Medicine Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients. For more information, please visit About PrismRA® PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world's largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit
Yahoo
11-06-2025
- Business
- Yahoo
Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design
Partnership integrates Scipher's PrismRA to deliver insights into therapy response segmentation WALTHAM, Mass., June 11, 2025--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA®, Scipher's proprietary precision medicine diagnostic, into an ongoing trial. PrismRA is designed to analyze a patient's molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies. This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit. "We are incredibly pleased to partner with one of the world's leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process," said Reg Seeto, CEO of Scipher Medicine. "This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently." Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry. The specific terms of the collaboration were not disclosed. About Scipher Medicine Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients. For more information, please visit About PrismRA® PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world's largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit View source version on Contacts Jaclyn Sign in to access your portfolio
